Neutrolis is working on inflammatory diseases related to uncontrolled neutrophilic inflammation. These diseases include lupus and sepsis. The company has a proprietary genetic technology platform and is working to develop drugs that neutralize excessive neutrophilic inflammation in addition to a companion diagnostic that could be used to identify appropriate patients.
2 articles with Neutrolis
On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral.